Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pomalidomide, Ixazomib, and Dexamethasone (PId) With or Without Intensification by Cyclophosphamide (PICd): A Phase II Study in Relapsed or Refractory Multiple Myeloma

NCT03731832 is registered in ClinicalTrials.gov with GWT-TUD GmbH as lead sponsor.

NCT NCT03731832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03731832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pomalidomide, Ixazomib, and Dexamethasone (PId) With or Without Intensification by Cyclophosphamide (PICd): A Phase II Study in Relapsed or Refractory Multiple Myeloma
Lead sponsor
GWT-TUD GmbH
Phase
Phase 2
Overall status
Completed
Start date
September 20, 2018
Completion date
April 22, 2024
Enrollment
66 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma